Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the...

This article originally appeared in OpenSecrets. Sign up for their weekly newsletter to receive stories like this one in your inbox.Novo Nordisk —...

By Gabriella Peralta and PA Staff The GHA is awaiting further guidance after UK health officials have given the green light for a weight-loss jab to...

In the most recent trading session, Eli Lilly (LLY) closed at $807.79, indicating a +0.39% shift from the previous trading day.

Shares of Eli Lilly are up 150% over the last 2 years as investors are bullish about the new weight loss drugs. Is it too hot to handle?

Investor focus is likely to be on the sales numbers of Lilly's (LLY) tirzepatide medicines Mounjaro and Zepbound.

Lilly’s Kisunla Approved to Treat Early Symptomatic Alzheimer's Disease In July, the FDA cleared Eli Lilly’s Kisunla (donanemab-azbt), an...

Pfizer (PFE) beats second-quarter estimates for earnings and sales. It raises 2024 earnings as well as revenue expectations.

AstraZeneca (AZN), Sanofi (SNY) and AbbVie (ABBV) announce second-quarter results. Merck (MRK) and Pfizer's (PFE) phase III studies achieve primary...